Ignyta Announces Submission Of IND For RXDX-101
Published: Feb 27, 2014
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.
Help employers find you! Check out all the jobs and post your resume.